Skip to content
★ Sign in to follow
Jilin Aodong Pharmaceutical Group Co., Ltd. logo

Jilin Aodong Pharmaceutical Group Co., Ltd. Stock: price and insider trades · China

吉林敖东

CN·Mcap CN¥20.6BHealth Care

No insider purchase over the last 90 days. The latest, by 郭淑芹, was filed 26 Jul 2024.

Jilin Aodong Pharmaceutical Group Co., Ltd.: what insiders have been doing

Every trade that managers of Jilin Aodong Pharmaceutical Group Co., Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector and is based in Dunhua, People's Republic of China. It was founded in 1993. No insider at Jilin Aodong Pharmaceutical Group Co., Ltd. has published a filing in the past twelve months. The most recent one dates from 26 July 2024.

Looking back to 2024, when coverage begins, insiders filed 2 purchases and no sales.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.

Insider Decl.
2
Thresholds
n/a
Buy Volume
€1M
2 ops. · all time
Sell Volume
n/a
n/a

Since the insiders bought

  • Filed 26 Jul 2024 · 835 days ago · €532k
    +49.4%
    Entry CN¥13.06 · Close at T+365 CN¥19.51
  • Filed 26 Jul 2024 · 835 days ago · €582k
    +49.4%
    Entry CN¥13.06 · Close at T+365 CN¥19.51

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 5,473 of 26,914 companies
66.8
score / 100
Value
66
Quality
68
FCF yld0.7%
Earn yld12%
EV/EBITDA8.5x
ROE10%
Gross mgn48%
Net mgn·
Debt/EBITDA0.8x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥17.23
Analyst consensus
·
Income statement
RevenueCN¥2.3B
Gross profitCN¥1.1B48% margin
EBITDACN¥2.7B115% margin
Net incomeCN¥2.4B141.2% margin
Valuation
PER (trailing)6.4x
P/Book0.6x
Beta0.53
Balance sheet & cash
Market capCN¥20.6B
Total debtCN¥2.2B
Free Cash FlowCN¥143.8M
Debt / Equity7%
Profitability & ownership
ROE10.0%
ROA-0.2%
% insiders33.4%
% institutions6.9%
Last declaration on 26 July 2024
Declarations2 total
  • ▲
    董事,高管Executives
    4M CNY27SZSE
    320,000 shares100.0% of flowA股XSHESZSE:173000007890838370
    Canonical exit: 24 Oct 2024 (T+90)
  • ▲
    董事Executives
    5M CNY27SZSE
    350,000 shares100.0% of flowA股XSHESZSE:173000007890838270
    Canonical exit: 24 Oct 2024 (T+90)

2 of 2 declarations

About Jilin Aodong Pharmaceutical Group Co., Ltd.

Jilin Aodong is a company specializing in the health and pharmaceutical sector, offering various pharmaceutical products. It is listed on the XSHE market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations